BIOQUAL Presents Financial Results for Fiscal Year 2023
- None.
- 2023 revenue decreased by 5.3% to $62,663,804 compared to 2022 revenue of $66,150,373.
- 2023 net income decreased by 84.1% to $835,548 compared to 2022 net income of $5,260,569.
- The company faces risks and uncertainties, including the ability to extend current government contracts and obtain new contracts.
- Investors should consider these factors before making investment decisions.
|
|
2023 |
|
2022 |
|
Revenue |
$ |
62,663,804 |
$ |
66,150,373 |
|
Income Before Income Tax |
$ |
1,133,242 |
$ |
6,576,784 |
|
Net Income |
$ |
835,548 |
$ |
5,260,569 |
|
Basic Earnings per Share |
|
|
|||
of Common Stock |
$ |
.93 |
$ |
5.88 |
|
Diluted Earnings per Share |
|
|
|||
of Common Stock |
$ |
.93 |
$ |
5.88 |
|
Weighted Average |
|
|
|||
Number of Shares Outstanding |
|
|
|||
For Basic Earnings Per Share |
|
894,416 |
|
894,416 |
|
Weighted Average |
|
|
|||
Number of Shares Outstanding |
|
|
|||
For Diluted Earnings Per Share |
|
894,416 |
|
894,423 |
|
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230920984660/en/
Mark G. Lewis, Ph.D., CEO (240-404-7654)
Source: BIOQUAL, Inc.
